(AGENPARL) - Roma, 29 Luglio 2025 - (AGENPARL) – Tue 29 July 2025 Lund, Sweden, 29 July 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA)
today announced three leadership appointments. Brian Gorman joins Hansa as Chief
Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has
been appointed Chief Human Resources Officer (CHRO), effective August 4; and
Kerstin Falck Lagercrantz will join the company September 1, as Vice President
Corporate Affairs. These three experienced executives will support Hansa’s
growth and further enhance the company’s expertise across legal, human resources
and corporate affairs.
Brian Gorman is an accomplished legal and business executive with more than 20
years of global experience in advising corporate boards and management teams.
Brian joins Hansa from Sinclair Pharma Ltd., a global medical aesthetics
company, where he was Chief Legal Officer supporting the company’s global
expansion efforts. Prior to Sinclair, Brian was Group General Counsel at
Calliditas Therapeutics, where he guided the company through its acquisition by
Asahi Kasei Corporation of Japan. Previously, Brian was Executive Vice
President, Corporate Development and General Counsel at Opiant Pharmaceuticals,
where he played a key role in its acquisition by Indivior PLC. Earlier in his
career, Brian held senior leadership roles at Endo Pharmaceuticals and
AstraZeneca. Brian began his career at international law firm Cleary Gottlieb
Steen & Hamilton, and he is a graduate of Gettysburg College and the Villanova
University School of Law.
Sandra Frithiof brings over 25 years of experience in human resources in
different industries, to Hansa. Most recently, Sandra was HR Director at Ayvens
Sweden AB, a global leader in the mobility sector. Prior to Ayvens, Sandra was
VP Human Resources at Calliditas Therapeutics, where she built the Global HR
organization to support the company’s entry into the US market. Previously,
Sandra was Head of HR and COO at Ramberg Advokater, a Swedish law firm and
earlier in her career, Sandra held HR positions at Karolinska University
Hospital, UTC, CGI and Manpower Group. Sandra has a bachelor’s degree in human
resource management from Örebro University, Sweden. Ms Frithiof will replace
Anne Säfström Lanner, CHRO, who will leave the organization.
Brian Gorman and Sandra Frithiof will report to CEO Renée Aguiar-Lucander and be
members of the Executive Committee.
Kerstin Falck Lagercrantz will join Hansa from Pfizer AB, where she has spent
over 20 years in various positions in corporate affairs and commercial
operations. Between 2014-2022, Kerstin held the role of Corporate Affairs
Director where she was responsible for external communications, patient affairs,
corporate social responsibility and crisis and issues management. During this
time, she successfully implemented agreements and influenced several health
policies during the COVID-19 pandemic. In addition, Kerstin has held several
positions with SwedenBIO, including member of the board, and multiple roles with
LIF (Swedish Pharmaceutical Industry Association). She has a Degree of Bachelor
of Science in Business Administration and Economics, from Uppsala University,
Sweden. Ms Falck Lagercrantz will report to Maria Törnsén, Chief Operating
Officer and US President, and she replaces Stephanie Kenney, former VP Corporate
Affairs, who has left Hansa.
“We are very pleased to welcome Brian, Sandra and Kerstin to Hansa. They bring
invaluable experience in their respective areas of expertise, which will be
critical as we step up our US pre-commercial activities, subject to data from
two Phase 3 readouts and our first BLA submission” said CEO Renée Aguiar
-Lucander.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/22mZHueQk3C5Whb5CMtM5QJuQMvhrqwADS5WqwjEjGNCg9TYkT1vh8nY3XZ5SePSvq6cpRwxnajWrHk7o8zwv76DZp1TNJHPAkHXzecd6rS7jY.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/22mZHueQk3C5Whb5CMtM5QJuQMvhrqwADS5WqwjEjGNCg9TYkT1vh8nY3XZ5SePSvq6cpRwxnajWrHk7o8zwv76DZp1TNJHPAkHXzecd6rS7jY.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Resistenza antimicrobica, allarme OMS: solo 42 Paesi su 183 dichiarano di aver finanziato e attuato i piani nazionali
- Dieta Mediterranea, Lollobrigida: patrimonio da tutelare e trasmettere alle nuove generazioni
- La condizione di insularità: dal riconoscimento costituzionale alle misure di contrasto – Martedì alle 15 diretta webtv
- Giornata Mondiale contro tumore cervice uterina – Martedì Montecitorio si illumina di verde “teal”
- Diritti umani, audizione Nunez, deputata Ecuador – Martedì alle 13 diretta webtv
- Il Natale di Verona in tavola – I sapori, la storia, le tradizioni della città di Romeo e Giulietta – Martedì alle 15.30 diretta webtv – Videomessaggio di Fontana
- Premio letterario nazionale Alsium Città di Ladispoli – Martedì alle 12 diretta webtv
- Misure di contrasto all’evasione fiscale, sicurezza delle banche dati dell’anagrafe tributaria e tutela della riservatezza dei dati dei contribuenti – Martedì alle 10 diretta webtv – Messaggio di Fontana
- Finanze, interrogazioni a risposta immediata – Ministero dell’Economia e delle Finanze – Martedì alle 13 diretta webtv
- Audizione su rischio idrogeologico – Martedì alle 13 diretta webtv